Logos Global Management as of Sept. 30, 2024
Portfolio Holdings for Logos Global Management
Logos Global Management holds 55 positions in its portfolio as reported in the September 2024 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
|---|---|---|---|---|---|
| Ideaya Biosciences (IDYA) | 7.2 | $67M | 2.1M | 31.68 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 5.9 | $55M | 1.3M | 43.89 | |
| Revolution Medicines (RVMD) | 5.9 | $54M | 1.2M | 45.35 | |
| Disc Medicine (IRON) | 5.0 | $46M | 935k | 49.14 | |
| Janux Therapeutics (JANX) | 4.9 | $45M | 1.0M | 45.43 | |
| Olema Pharmaceuticals (OLMA) | 4.1 | $38M | 3.2M | 11.94 | |
| Vaxcyte (PCVX) | 3.7 | $34M | 300k | 114.27 | |
| Immunovant (IMVT) | 3.4 | $31M | 1.1M | 28.51 | |
| Celldex Therapeutics Com New (CLDX) | 3.3 | $31M | 900k | 33.99 | |
| Ocular Therapeutix (OCUL) | 3.3 | $31M | 3.5M | 8.70 | |
| Ionis Pharmaceuticals (IONS) | 3.2 | $30M | 750k | 40.06 | |
| Erasca (ERAS) | 3.2 | $30M | 11M | 2.73 | |
| Apellis Pharmaceuticals Call Option (APLS) | 3.1 | $29M | 1.0M | 28.84 | |
| Merus N V (MRUS) | 3.1 | $29M | 575k | 49.96 | |
| Galapagos Nv Spon Adr (GLPG) | 2.5 | $23M | 800k | 28.79 | |
| Akero Therapeutics (AKRO) | 2.5 | $23M | 800k | 28.69 | |
| Design Therapeutics (DSGN) | 2.4 | $23M | 4.2M | 5.38 | |
| Vera Therapeutics Cl A (VERA) | 2.4 | $22M | 500k | 44.20 | |
| Cogent Biosciences (COGT) | 2.3 | $22M | 2.0M | 10.80 | |
| Cytokinetics Com New (CYTK) | 2.3 | $21M | 400k | 52.80 | |
| Bicara Therapeutics (BCAX) | 2.2 | $20M | 800k | 25.47 | |
| Sarepta Therapeutics (SRPT) | 2.0 | $19M | 150k | 124.89 | |
| Annexon (ANNX) | 1.7 | $15M | 2.6M | 5.92 | |
| Travere Therapeutics (TVTX) | 1.7 | $15M | 1.1M | 13.99 | |
| Enliven Therapeutics (ELVN) | 1.4 | $13M | 495k | 25.54 | |
| Beam Therapeutics (BEAM) | 1.3 | $12M | 500k | 24.50 | |
| Edgewise Therapeutics (EWTX) | 1.3 | $12M | 450k | 26.69 | |
| Bicycle Therapeutics Sponsored Ads (BCYC) | 1.2 | $11M | 500k | 22.63 | |
| Y Mabs Therapeutics (YMAB) | 1.1 | $11M | 800k | 13.15 | |
| Arvinas Ord (ARVN) | 1.1 | $9.9M | 400k | 24.63 | |
| Trevi Therapeutics (TRVI) | 1.0 | $9.2M | 2.8M | 3.34 | |
| Nuvalent Inc-a (NUVL) | 0.8 | $7.7M | 75k | 102.30 | |
| Compass Pathways Sponsored Ads (CMPS) | 0.8 | $7.3M | 1.2M | 6.30 | |
| Oruka Therapeutics (ORKA) | 0.7 | $6.3M | 257k | 24.51 | |
| Rocket Pharmaceuticals (RCKT) | 0.6 | $6.0M | 325k | 18.47 | |
| Spyre Therapeutics Com New (SYRE) | 0.6 | $5.9M | 200k | 29.41 | |
| Dyne Therapeutics (DYN) | 0.6 | $5.7M | 160k | 35.92 | |
| Astria Therapeutics (ATXS) | 0.6 | $5.5M | 500k | 11.01 | |
| Fulcrum Therapeutics Call Option (FULC) | 0.6 | $5.4M | 1.5M | 3.57 | |
| Cybin Com New (CYBN) | 0.6 | $5.3M | 600k | 8.89 | |
| Engene Holdings (ENGN) | 0.6 | $5.3M | 800k | 6.60 | |
| Avalo Therapeutics Com New (AVTX) | 0.6 | $5.1M | 539k | 9.50 | |
| Lineage Cell Therapeutics In (LCTX) | 0.5 | $4.5M | 5.0M | 0.91 | |
| Rapport Therapeutics (RAPP) | 0.4 | $4.1M | 209k | 19.46 | |
| Silence Therapeutics Ads (SLN) | 0.4 | $3.6M | 200k | 18.18 | |
| Atyr Pharma Com New (ATYR) | 0.4 | $3.5M | 2.0M | 1.76 | |
| Nextcure (NXTC) | 0.4 | $3.4M | 2.5M | 1.37 | |
| Adverum Biotechnologies Com New (ADVM) | 0.3 | $2.9M | 417k | 7.02 | |
| Artiva Biotherapeutics (ARTV) | 0.2 | $2.1M | 145k | 14.68 | |
| Unicycive Therapeutics (UNCY) | 0.2 | $2.1M | 5.1M | 0.41 | |
| Allakos (ALLK) | 0.2 | $1.9M | 2.9M | 0.65 | |
| Neumora Therapeutics (NMRA) | 0.1 | $1.3M | 100k | 13.21 | |
| Io Biotech (IOBT) | 0.1 | $519k | 494k | 1.05 | |
| Skye Bioscience Com New (SKYE) | 0.0 | $391k | 100k | 3.91 | |
| Boundless Bio (BOLD) | 0.0 | $204k | 59k | 3.47 |
